PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

BACKGROUND: Immunotherapy using programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors seems less effective in non-small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations. Varied responses to PD-1/PD-L1 inhibitors have recently been...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tiantian, Jiao, Jin, Huo, Ran, Li, Xiaofang, Fang, Guotao, Zhao, Qi, Liu, Weiwei, Han, Xiao, Xi, Chenglin, Wang, Yanan, Shang, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389166/
https://www.ncbi.nlm.nih.gov/pubmed/35992815
http://dx.doi.org/10.3389/fonc.2022.922899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389166/
https://www.ncbi.nlm.nih.gov/pubmed/35992815
http://dx.doi.org/10.3389/fonc.2022.922899

Ejemplares similares